DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM

UM-1098 的开发：一种新型合成 TH17 诱导佐剂和递送系统

• 批准号: 10935819
• 负责人: JAY EVANS
• 金额: $ 241.99万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2028-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10935819
• 关键词: Adjuvant; Antigens; Aspergillus fumigatus; Bordetella pertussis; Candida albicans; Cells; Chemistry; Clinical Trials; Contractor; Contracts; Development; Drug Kinetics; Excretory function; Family suidae; Formulation; Human; Humoral Immunities; Immune response; Immunity; Investigation; Ligands; Mediating; Metabolism; Modeling; Mus; Mycobacterium tuberculosis; Mycobacterium tuberculosis antigens; National Institute of Allergy and Infectious Disease; Production; Property; Pseudomonas aeruginosa; Rodent; Safety; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship; System; Toxicology; Trehalose; Vaccination; Vaccine Adjuvant; Vaccines; absorption; combat; efficacy study; immunogenicity; improved; manufacture; mouse model; nanoparticle delivery; nonhuman primate; novel; novel vaccines; pathogen; pathogenic bacteria; pathogenic fungus; programs; receptor; research clinical testing; thermostability

The development and clinical evaluation of safe and effective Th17 inducing adjuvants is urgently needed for the advancement of vaccines to combat the ongoing threat of bacterial and fungal pathogens including Mycobacterium tuberculosis (Mtb), Bordetella pertussis, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumonia, Candida albicans, Aspergillus fumigatus and others. Vaccination against TB and other bacterial and fungal pathogens has been hampered by the lack of appropriate adjuvants for inducing Th17 immunity. Thus, the next generation of vaccine adjuvants capable of inducing broadly protective immune responses against emerging bacterial and fungal pathogens represents a critical unmet need. This Adjuvant Development Contract will advance one such adjuvant – UM-1098: a Th17 inducing synthetic Mincle ligand– towards human clinical trials. UM-1098 was identified through the NIAID Adjuvant Discovery Program via a comprehensive and iterative structure-activity relationship (SAR) investigations to identify a novel synthetic diaryl trehalose Mincle receptor ligand paired with a novel nanoparticle delivery system. This adjuvant and delivery system has a well-established safety and efficacy profile in mice, pigs and non-human primates (NHPs) across multiple highly relevant antigen/pathogen platforms including TB and Bordetella pertussis. The advantages of UM-1098 over previously developed Mincle adjuvants includes improved formulation physiochemical properties, thermostability, robust safety profile, and most importantly, superior antigen-specific Th17, Th1, and humoral immunity across rodents, pigs and NHPs. When co-administered with an antigen, UM-1098 adjuvant induces durable cell-mediated and humoral immunity with demonstrated protection against Mtb and Bordetella pertussis challenge.

为了对抗结核分枝杆菌、百日咳杆菌、金黄色葡萄球菌、铜绿假单胞菌、肺炎链球菌、白色念珠菌、烟曲霉菌等细菌和真菌的持续威胁，迫切需要安全有效的Th17诱导佐剂的开发和临床评估。由于缺乏适当的佐剂来诱导Th17免疫，针对结核病和其他细菌和真菌病原体的疫苗接种一直受到阻碍。因此，能够诱导针对新出现的细菌和真菌病原体的广泛保护性免疫反应的下一代疫苗佐剂是一个关键的未得到满足的需求。这份佐剂开发合同将推动一种这样的佐剂-UM-1098：一种诱导合成Mincle配体的Th17进入人体临床试验。UM-1098是通过NIAID佐剂发现计划通过全面和迭代的构效关系(SAR)研究确定的，以确定与新的纳米颗粒递送系统配对的新型合成二芳基海藻糖Mincle受体配体。这种佐剂和递送系统在小鼠、猪和非人类灵长类动物(NHP)中具有良好的安全性和有效性，跨越包括结核病和百日咳杆菌在内的多种高度相关的抗原/病原体平台。与以前开发的Mincle佐剂相比，UM-1098的优势包括改进的配方物理化学性质、热稳定性、强大的安全性，以及最重要的是，卓越的抗原特异性Th17、Th1和对啮齿动物、猪和NHP的体液免疫。当与抗原联合使用时，UM-1098佐剂诱导持久的细胞介导和体液免疫，并证明对结核杆菌和百日咳杆菌的攻击具有保护作用。